Navigation Links
Breakthrough in RSV research to help infected children
Date:5/23/2014

Researchers at Le Bonheur Children's Hospital and the University of Tennessee Health Science Center announced results today from a clinical trial of a drug shown to safely reduce the viral load and clinical illness of healthy adult volunteers intranasally infected with respiratory syncytial virus (RSV).

Detailed results of this study were presented by lead researcher Infectious Disease Specialist John DeVincenzo, MD, this week during a poster discussion session at the American Thoracic Society 2014 International Conference in San Diego. He serves as medical director of the Molecular and Viral Diagnostics Laboratories at Le Bonheur Children's Hospital and also serves as a professor of Pediatrics and professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee College of Medicine.

RSV is the most common cause of lower respiratory tract infections in young children in the United States and worldwide. It hospitalizes 125,000 children in the United States each year, and was the cause for 1.5 million outpatient visits, according to the Centers for Disease Control and Prevention (CDC). DeVincenzo and his fellow researchers have been part of virtually every experimental therapeautic advancement, developmental pathway and antiviral therapy created to tackle the virus in the past 15 years. Learn more about his research at lebonheur.org/promise.

The Phase 2a challenge study of Gilead Sciences Inc.'s GS-5806, an investigational oral RSV fusion inhibitor, achieved primary and secondary endpoints of lower viral load, improvements in total mucus weight and symptom diary score compared to placebo. Volunteers in the study were given the oral drug after being infected with RSV using the experimental challenge model based on a clinical isolate from an infant hospitalized with RSV bronchiolitis which can be safely used to infect adults, and that was developed by DeVincenzo in 2007 to test proof-of-concept antivirals.

"No effective antiviral treatments currently exist for RSV, which is the leading cause of severe childhood respiratory infections, and is increasingly recognized as a major cause of serious adult respiratory infections," said DeVincenzo. "Based on the reductions in viral load, reduced clinical symptoms, as well as the safety profile observed in this adult challenge study, clinical trials in naturally infected patients should now be explored."


'/>"/>

Contact: Sara Burnett
Sara.Burnett@lebonheur.org
901-487-0739
Le Bonheur Children's Hospital
Source:Eurekalert

Related medicine news :

1. Breakthrough: Nasal spray may soon replace the pill
2. Breakthrough Research Provides Valuable Insight On Cause Of Alzheimer’s
3. Diverticulitis Breakthrough Review Indicates If This Book Is Reliable – HealthReviewCenter
4. MD Anderson researcher Jim Allison wins Breakthrough Prize for his innovative cancer immunology rese
5. Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells
6. Pacific Northwest Dry Eye Sufferers Gain Access to Breakthrough Treatment at Specialty Eyecare Group
7. Noted Experts to Lead Breakthrough Conversation at Center for Hispanic Leadership, December 2nd Hispanics in Healthcare Forum
8. Study reveals potential breakthrough in hearing technology
9. Children’s Cancer & Blood Foundation Breakthrough Ball Gala Honored Margo & John Catsimatidis, Amar’e Stoudemire and Dr. Patricia J. Giardina
10. Effective and Safe Cancer Vaccine? Breakthrough Alternative Cancer Treatment Available Through Special Research Program
11. Voices Against Brain Cancer Comments On Breakthrough Brain Surgery Technique
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology: